Prelude Therapeutics Incorporated
PRLD
$3.94
$0.102.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 39.14% | 21.76% | 15.01% | 4.26% | -1.82% |
| Total Depreciation and Amortization | -6.40% | -3.44% | 10.41% | 18.41% | 35.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.68% | -28.53% | -30.62% | -17.53% | -18.35% |
| Change in Net Operating Assets | 748.19% | 573.84% | -221.28% | -176.18% | 137.72% |
| Cash from Operations | 58.46% | 45.28% | 5.26% | -4.07% | 3.12% |
| Capital Expenditure | 96.17% | 91.23% | 93.48% | 92.27% | 82.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.17% | -41.15% | 75.19% | 29.40% | 760.15% |
| Cash from Investing | -100.19% | -40.73% | 79.29% | 33.00% | 665.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 90.36% | 47.34% | -47.13% | -428.13% | -- |
| Issuance of Common Stock | 5,637.30% | 5,604.10% | -99.15% | -98.94% | -99.68% |
| Repurchase of Common Stock | -46.51% | 68.52% | 60.42% | 47.06% | -30.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -167.27% | -- | 100.00% | 69.05% | -137.04% |
| Cash from Financing | 9,371.43% | 20,780.00% | -100.64% | -101.14% | -100.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.16% | 271.44% | 847.35% | -250.22% | 139.19% |